Nanotech Stem Cells, Order Now!
discuss this article
A good rule to follow: hold onto your wallet when two exciting, complicated fields of research are combined. Nature reported earlier this spring on a good example of this, the announcement by a small biotech called Primegen that they'd used carbon nanotubes to reprogram stem cells. (Here's a good article from VentureBeat on the same announcement, and there's an excellent piece on the announcement and the company in Forbes).
Stem cells and nanostructures are two undeniably hot areas of research. And also undeniable is that fact that they're both in their very early days - the amount of important information we don't know a...
Source: In the Pipeline - May 16, 2008 Tags: Biological News
Hexamine (Self-assembly is neat)
discuss this article
Hexamine is a nitrogenous analogue of adamantane. Read the rest of this post... | Read the comments on this post...
Source: Molecule of the Day - May 15, 2008 Tags: Explosives
Copper: A Gentleman's Disagreement
discuss this article
I was running a copper-catalyzed coupling reaction the other day when my summer intern asked me how it worked. I showed her the mechanism that the authors of the paper had proposed, but pointed out that it was mostly hand-waving. The general features are probably more or less right: the copper iodide presumably does form some kind of soluble complex with the amino acid that’s needed in the reaction mix, and that may well form some sort of complex with the aryl halide, which opens up the ring to nucleophilic substitution, etc. If this were an exam, I’d give full points for that one.
But a lot of these couplings are, as...
Source: In the Pipeline - May 15, 2008 Tags: Inorganic Chemistry
Adamantane (That's like, what, a million diamonds for $400?)
discuss this article
Adamantane is a sort of triple-fused-cyclohexane structure: Read the rest of this post... | Read the comments on this post...
Source: Molecule of the Day - May 14, 2008
Summer Student Time
discuss this article
I have a summer intern this year, and she has (so far) not caused anything to burst into flames. That’s the first thing you ask of a summer student, and the fact that she’s gotten several reactions to work is just a welcome extra. A summer with no laboratory bonfires will be a successful summer, as far as I’m concerned.
That’s because I’ve experienced the alternative, as I’ve detailed here before. If most of the lab fire stories you hear start out with the phrase “We had this solvent still. . .”, the rest of them all seem to begin with “We had this summer undergrad student. . .” (You can imagine the fl...
Source: In the Pipeline - May 14, 2008 Tags: Life in the Drug Labs
In Which I Hate A Wonder Drug
discuss this article
Schering-Plough has had its share of troubles over the years, but the company has also seen itself saved by some pretty unlikely compounds. Vytorin (ezetimibe) is the example I’ve spoken about here, and if the drug doesn’t seem like a savior at the moment, well, you have to keep in mind that it was the biggest thing for them since Claritin went off-patent ten years ago.
Now there’s another one potentially coming up. Expectations are building for a thrombin receptor antagonist compound, SCH 530348. And I have a history with this one, too: while the labs down one hallway from me were discovering ezetimibe, down the ot...
Source: In the Pipeline - May 13, 2008 Tags: Cardiovascular Disease
I’m not going to renew my ACS membership
discuss this article
I’m not going to any ACS conferences this year, so there’s no financial reason for me to do it, but more importantly, I’m pretty sick of the ACS. Aside from a few decent reads in C&EN, I can’t help but feel as though I’m getting fucked by those people.
Firstly, the membership costs come out of my pocket. Which is fine, since it’s not yet over $100. Local dues and whatnot, it’s about $75 or something, roughly the cost of GROCERIES. And since student stipends are approximately $1000 more a year than the average cost of living (if you pretend the average cost of living was $2000 l...
Source: The Chem Blog - May 12, 2008 Authors: Kyle Finchsigmate Tags: Organic Chemistry
Explaining It All
discuss this article
One of the reasons I starting this blog was that many people I met were interested in my job. Very few of them had ever talked to someone who discovered new medicines for a living, and a surprising number of them (well, surprising to me) had no idea of where medicines came from in the first place.
Talking to such folks (interested, but with no particular training in science) gave me some good practice in explaining the work. It helps that the kind of work I do is actually fairly easy to explain. There are a lot of details – as with any branch of science, the closer you look, the more you see – but I haven’t run acr...
Source: In the Pipeline - May 12, 2008 Tags: Life in the Drug Labs
More on Volatile Buffers
discuss this article
Previously I've mentioned triethylammonium acetate, and ammonium carbonate. These are salts formed by mixtures of volatile stuff - triethylamine, acetic acid, ammonia, and carbon dioxide. Awhile ago I made one I hadn't ever made before. Read the rest of this post... | Read the comments on this post...
Source: Molecule of the Day - May 9, 2008
Mein Kugelrohr
discuss this article
I have a compound that refuses to be pure and I’m thinking about just taking it on impure (it’s about 90% pure). I’ve attempted a couple ways to purify this oil, but nothing really works. Fractional distillation does indeed help, but I’ve gotten to the point where the ratio of impurities no longer changes, which makes me think I’ve got an azeotrope. I’m doing a derivative of the “general” reaction shown below, which is a bit easier to purify.
You can imagine columns are worthless, as all the compounds fly right off in pure hexanes, pentanes, pet ethers… nothing works ...
Source: The Chem Blog - May 9, 2008 Authors: Kyle Finchsigmate Tags: In teh lab Instrumetnal Organic Chemistry
Merck Bails on Natural Products
discuss this article
Every few years, you hear talk of a renaissance in natural products-based drug discovery. Well, this news should postpone the next round of optimism for a bit longer: Merck is cutting their natural products program entirely. They've had a long history in that area, but no more. That C&E News item includes an interesting detail:
"The company disclosed that it would also be closing its 50-year-old natural products drug discovery operation based in Madrid after a Merck executive inadvertently included the plan in a PowerPoint presentation to an audience that included Merck employees."
Smooth move. I'm sure some interesting ...
Source: In the Pipeline - May 8, 2008 Tags: Drug Industry History
Triacetin (Always liquid, always semi-edible)
discuss this article
Triacetin is the glycerol triester of acetic acid: Read the rest of this post... | Read the comments on this post...
Source: Molecule of the Day - May 7, 2008 Tags: Food
Science By Country
discuss this article
Update: here's the map that I was imagining, thanks to Andy in the comments section. It's on the Worldmapper site linked to below, but I missed it while putting the post together. Most of my speculations turned out to be reasonable, although Venezuela (for one) looks a bit better than I thought it would, and Iran looks a bit worse. Africa and the Islamic world are, as hypothesized, almost invisible.
I’d like to see a map of the world with country size dependent on the number of scientific publications and patents – perhaps you’d want to use publications per capita, or per educated capita. That's a cartogram, and alt...
Source: In the Pipeline - May 7, 2008 Tags: General Scientific News
Highlights of Research that I missed while bitching about other shit
discuss this article
This isn’t C&E news concentrates, but I want to cram a few in that I missed over the last few months. I’ve read and loved and you’ll love these advances in the field of chemistry:
First: DOI: 10.1126/science.1152692. Fucking brilliant piece from the Baker lab representing state of the art fuckability of proteins. The title: “De Novo Computational Design of Retro-Aldol Enzymes” gives you a half assed idea of what’s actually going on. Where the typical “state of the art” to select for proteins that do specific chemistry is to essentially make a fuck-ton of proteins and run ...
Source: The Chem Blog - May 7, 2008 Authors: Kyle Finchsigmate Tags: Organic Chemistry
MPLCs for the people pt 2
discuss this article
I had to take a break from writing the supporting info for a paper I’m doing. Multi colored NMRs and J values and ChemDraw and various other spectra are driving me batshit crazy. Here is a quick post to answer some common questions about the MPLC:
Q: How many grams can you load?
A: As many as you wish. It becomes cumbersome above 10 grams and hardly worth it below 40 mg. I’ve run as little as 10 mg, however, and gotten pretty good separation.
Q: Can you do gradients?
A: Yes. As stated, the gradients are fully adjustable since it’s very, very ghetto. You have two bottles and one is pulling solvent out of ...
Source: The Chem Blog - May 6, 2008 Authors: Kyle Finchsigmate Tags: Organic Chemistry
Alzheimer's: A Report From the Front
discuss this article
Several recent papers in Neurology offer some interesting ideas on Alzheimer's disease. The one that's getting some headlines today suggests that long-term use of ibuprofen has a protective effect against the disease. Actually, the authors looked at all sorts of non-steroidal antiinflammatory drugs, but the correlation was strongest for ibuprofen. (That may be just because it's used so much, however, and not some intrinsic property of that specific drug). Interestingly, although some NSAIDs have been shown to inhibit formation of beta-amyloid (the protein fragment implicated for many years in Alzheimer's), no particular ef...
Source: In the Pipeline - May 6, 2008 Tags: Alzheimer ' s Disease
Fmoc (Amino acid condoms)
discuss this article
Automated solid-phase synthesis of biomolecules defines 20th century biology. I previously covered a protecting group that is ubiquitous in DNA synthesis, but the Nobel was actually awarded for peptide chemistry. Read the rest of this post... | Read the comments on this post...
Source: Molecule of the Day - May 5, 2008 Tags: Synthesis
Naming of Names
discuss this article
We order chemicals from all sorts of suppliers – big, reputable outfits like Sigma-Aldrich-Fluka all the way down to places that none of us even have heard of before. In those latter cases, the primary question is always whether or not the reagent will actually show up, and the secondary one is how long it’ll take. There are some of those small suppliers who pad their catalog with things that aren’t exactly available, not yet – but hey, they will be if someone orders them. They’ll just tell you it’s back-ordered, and tell someone in the lab to get cracking.
And when you get your compound in, they arrive in var...
Source: In the Pipeline - May 5, 2008 Tags: Life in the Drug Labs
"Not Useful" Means "Not Approvable", Right?
discuss this article
One recent drug industry setback I haven't noted around here - well, OK, to be more specific, it's a Merck setback, and boy must they be getting sick of those - is the FDA's "not approvable" letter for the Singulair/Claritin combination pill.
As the folks at the InVivoBlog note, it sure was hard, from one perspective, to see that one coming. After all, Claritin (loratadine) has an exemplary safety record and has been on the market for many years now, and Singulair (montelukast) has been selling in the billions of dollars as a stand-alone drug. No doubt many people have taken, and are taking, the two as separate pills. So ...
Source: In the Pipeline - May 2, 2008 Tags: Drug Development
Dichloromethane (Now healthier with 50% less chlorine!)
discuss this article
Chlorinated solvents are great solvents. The polarizability of chlorine, moderate electronegativity, moderate volatility, lack of acidic protons or reactivity - it all adds up to a great reaction medium. However, they usually are toxic. Read the rest of this post... | Read the comments on this post...
Source: Molecule of the Day - May 1, 2008 Tags: Synthesis
MPLCs for the people
discuss this article
I don’t like to run columns and I generally don’t. My syntheses are so bad assed, I generally work harder at figuring out purification methods that don’t require silica because columns are very, very wasteful and it hurts the earth and Al Gore’s feewings. That being said, most of my shit is purified on a column. But I’m both smart and lazy so I’ve used technology to make my life 900% easier by running flash chromatography once a month. My other column is a ghetto MPLC and I LOVE IT OMG LOL!!!!1!1one!.
An MPLC is the “medium pressure” variant of an HPLC, but they really couldn...
Source: The Chem Blog - May 1, 2008 Authors: Kyle Finchsigmate Tags: In teh lab Instrumetnal Organic Chemistry
O Pioneers!
discuss this article
Drug Discovery Today has the first part of an article on the history of the molecular modeling field, this one covering about 1960 to 1990. It’s a for-the-record document, since as time goes on it’ll be increasingly hard to unscramble all the early approaches and players. I think this is true for almost any technology; the early years are tangled indeed.
As you would imagine, the work from the 1960s and 1970s has an otherwordly feel to it, considering the hardware that was available. And that brings up another thing common to the early years of new technologies: when you look back on them from their later years, you w...
Source: In the Pipeline - May 1, 2008 Tags: In Silico
How Not To Do It: Diazomethane
discuss this article
This post will have one of those stories that I can’t vouch for personally, and I’m very glad of that. It involves making diazomethane, which will have already gotten the attention of the chemists in the crowd.
Diazomethane’s a very useful reagent, but it has to be treated the right way. You can’t buy it – no one will ship the stuff – so you have to make it fresh. (There are several such reagents). For many years there have been chemicals in the catalogs whose only real use has been to generate diazomethane when needed. Generally this involves treating some nasty N-nitroso compound with base in ether, then dis...
Source: In the Pipeline - April 30, 2008 Tags: How Not to Do It
Cordaptive Q and A
discuss this article
So why is Merck's stock dropping - again?
The FDA just unexpectedly handed them a "not approvable" letter for their latest drug, Cordaptive. Actually, we should stop calling it that, since they also told the company that they're not going to approve that name, either. What Merck's going to do with all their promotional freebies now, I can't imagine.
What's Cordaptive, or whatever it's called, anyway?
That's Merck's newest cardiovascular drug - although the active ingredient isn't new. It's niacin, also known as vitamin B3. It's been known for many years that niacin can both lower LDL cholesterol and raise HDL, as well as ...
Source: In the Pipeline - April 29, 2008 Tags: Cardiovascular Disease
Niacin (Nicotine vitamins?)
discuss this article
Niacin is also known as Vitamin B3. Interestingly, it's also called "nicotinic acid," and the similarity of the name to "nicotine" isn't coincidental: Read the rest of this post... | Read the comments on this post...
Source: Molecule of the Day - April 28, 2008 Tags: Medicine
A Salute
discuss this article
Dr. Warfield Teague is retiring this year, which makes me feel old. He was one of the professors who helped make me what I am today – in his case, partly by keeping me out of his chosen field of inorganic chemistry. It was a good move on his part; I’d surely have blown something up good and thoroughly when I got to grad school, such are the opportunities in that area.
Unfortunately for both him and for me, his Advanced Inorganic course ended up scheduled for 7:40 AM back in early 1983. I started out my college career with a barrage of classes at that hour, and made every one of them. My sophomore year, I only skipped ...
Source: In the Pipeline - April 28, 2008 Tags: Inorganic Chemistry
There is clearly a wall between us
discuss this article
I don’t want anyone taking the impression that I, Kyle muthafuckin Finchsigmate, am in any way disparaging those who do natural product total synthesis. You may have gotten that since sometimes people read comments and attribute them to the post author and, well, it confuses some people even more. I am not opposed to TS research. But… there are two generalizations about TS that I want to expel. Firstly, structural conformation is necessary by total synthesis and drug targets are often inspired by the complex structures of mother nature. You’ve got to do one to get the other. Secondly, it’...
Source: The Chem Blog - April 27, 2008 Authors: Kyle Finchsigmate Tags: In teh lab Organic Chemistry Sciency politics
Why Buy, Anyway?
discuss this article
I don’t want to say that this is a trend, but I notice that GSK is saying that they’re going to leave Sirtris more or less alone as well (as Takeda has said they’ll do with Millennium). The researchers in both shops should feel good about that, and not only because they’ll be keeping their jobs. They’re getting a vote of confidence in the most meaningful way that a large company can give that to its employees: by paying you money and not messing with you.
Of course, these deals have two sides to them. I don’t know what it’s like in Takeda back in Japan – my contacts inside the Japanese pharmaceutical indus...
Source: In the Pipeline - April 25, 2008 Tags: Business and Markets
$720 Million Worth of Sirtuin Research
discuss this article
Well, I’m back from a brief vacation, and catching up with the news. It looks like the big headline is GlaxoSmithKline’s offer for Sirtris: $720 million, which is a hefty premium (84%!) to what the company was trading for previously. Reckless waste of money, or canny deal?
I lean toward the latter, but I’ve long had a place in my heart for sirtuin research and its potential. It’s still a long shot, but it’s one of the most intriguing ones in the history of medicine. Actually, from one perspective, you wonder how long a shot it is: a biochemical pathway that seems to extend healthy life in yeast, roundworms, flie...
Source: In the Pipeline - April 24, 2008 Tags: Business and Markets
Isotopic food (Why was I not informed?)
discuss this article
Is paying $5/liter for Fiji water not cutting it? Trying to come up with a more environmentally abhorrent, gauche hydration accessory? How would you feel about $1,000/liter, along with some iffy health benefits? Read the rest of this post... | Read the comments on this post...
Source: Molecule of the Day - April 24, 2008 Tags: Medicine
Why Does Cyanide Pretend to be a Weak Field Ligand in [Cr(CN)5]3−?
discuss this article
Lord and Baik* Generally speaking, it is difficult to study Cr chemistry because many Cr complexes are paramagnetic. Computational modeling is also not easy due to spin contamination issues. This paper by Lord and Baik provides a rationale for the observation of (NEt4)3[Cr(CN)5] in a high-spin (S = 2) ground state, suggesting that one must consider both ligand−ligand electrostatic interactions and classical ligand−field arguments in order to have a full picture of spin-state energetic ordering in a transition metal complex. What they found here was that the Coulombic repulsion between the anionic cyanide ligands domina...
Source: Organometallic Current - April 23, 2008
Big Pharma’s big problem
discuss this article
A while back I was lucky enough to be accidentally selected to take a big shot from big pharma out to lunch while she was visiting. I say accidentally, because I’ve been a very vocal critic of big pharma’s business model, going so far as to actually do a seminar on the subject the first year I was in graduate school (kids, don’t do that.) My position isn’t that Big Pharma is evil and they’re out to get you, it’s that they’re big, stupid useless machines that pump out gobs of fluorinated shit for metabolic syndrome and boners and buy up little companies before their quarterly report...
Source: The Chem Blog - April 22, 2008 Authors: Kyle Finchsigmate Tags: Drugs! Organic Chemistry Sciency politics
Quick Note
discuss this article
Just wanted to let everyone know that there probably won't be a post for Monday - I'm doing some traveling, and will have irregular access to the internet. No doubt huge stories will break during the day, while I'm unable to comment on them! At any rate, we'll see if I can get something up for Tuesday. See you then!
Source: In the Pipeline - April 20, 2008 Tags: Blog Housekeeping
Druggies
discuss this article
So, out of about 375 of you (about 25% of Nature’s respondents) about 35% say that availability not being a factor you would essentially use some form of prescription drug to give yourself an intellectual boost, which is not too far above what Nature polled for people in the age group I assume my readership is in.
I mean, possibly 10% higher, but these polls are horribly inaccurate anyway, so I’ll just call everything even and say, maybe if availability weren’t an issue, But it’s not as high as another number. Apparently, almost 60% of you have already tried a drug for recreational purposes already...
Source: The Chem Blog - April 20, 2008 Authors: Kyle Finchsigmate Tags: Drugs! Sciency politics
Mercury Beating Heart
discuss this article
Oscillating reactions are neat; I should write up one of my favorites sometime... Here, electrons flow from iron metal to mercury (I) sulfate to chromium (VI) oxide. Listen to the video for a step-by step explanation... Read the rest of this post... | Read the comments on this post...
Source: Molecule of the Day - April 20, 2008 Tags: Inorganic
Molecules in the news...
discuss this article
A couple previous molecules of the day were in the news today: polylactide and lead chromate. Read the rest of this post... | Read the comments on this post...
Source: Molecule of the Day - April 18, 2008 Tags: Not Really a Molecule
Cut It Out. Cut It Out Now.
discuss this article
File this under “does no one any good”. As many of you will have seen, JAMA just published a report on various studies that Merck has conducted and published over the years on Vioxx. The conclusion was that the company basically wrote the papers, and then went shopping for well-known academic names as authors. No, this one isn’t going to be good for anyone involved.
There seems little doubt that this practice does go on. I’ve never been in a position to see it happen, but it’s been reported for years. There are whole companies whose business is “scientific writing and communication”, and some of these seem t...
Source: In the Pipeline - April 18, 2008 Tags: The Dark Side
Getting Smarter Already?
discuss this article
There have been several articles in Nature recently about performance-enhancing drugs. But these aren’t steroids or blood-cell therapies: they’re performance enhancers for scientists and engineers. Chief among them are Ritalin (methylphenidate), Provigil (modafinil), and various beta-blockers, to enhance concentration and wakefulness. The whole topic came to the fore last December, in an article suggestively titled "Professor's Little Helper". Here are the results of their informal readership poll. It's not a huge trend, at least not yet. The fraction of their self-selected sample who had never taken any such compound ...
Source: In the Pipeline - April 17, 2008 Tags: General Scientific News
Fun With Bacteria
discuss this article
A recent interview in Nature Reviews Drug Discovery with John Powers, formerly of the FDA, points out some problems in designing antibacterial drug trials. Some of these are unique to this area, although others we're stuck with wherever we go.
For one thing, it’s surprisingly hard to make sure, when you’re selecting patients, that the people you’re letting into the trial have the disease that you’re trying to treat. The example used is that some 5% of the patients who present with cough actually have pneumonia. Pneumonia is a very good disease to treat with antibacterial drugs, but you’d better make sure that yo...
Source: In the Pipeline - April 16, 2008 Tags: Infectious Diseases
Nickel-Catalyzed Decarbonylative Addition of Phthalimides to Alkynes
discuss this article
Kajita, Matsubara,* and Kurahashi*This is an interesting reaction to make isoquinolones. Their design was quite logical and it did work at the first try, although the yield of the desired product was only 18%. The authors managed to improve the yield by the introduction of electron withdrawing Ar groups. The mechanism was proposed to proceed by a nucleophilic attack of Ni(0) to the amide moiety (an oxidative addition of C-N to Ni) followed by decarbonylation, insertion of the alkyne to the phenyl C-Ni bond, and finally reductive elimination of the product to regenerate the Ni(0) catalyst. The fate of CO was not mentioned, ...
Source: Organometallic Current - April 16, 2008
Phytic acid (Think unositol? Think again...)
discuss this article
Phytic acid is an inositol derivative: Read the rest of this post... | Read the comments on this post...
Source: Molecule of the Day - April 16, 2008 Tags: Food
Inositol (Weird carbs)
discuss this article
Inositol is a sugar: Read the rest of this post... | Read the comments on this post...
Source: Molecule of the Day - April 15, 2008 Tags: Food
Walk Around Some
discuss this article
Not many chemists come into the drug industry knowing very much about biology. I certainly didn’t, not on the level that was needed. It’s not surprising, but it’s also not as much of a handicap as you’d think, at least not at first.
That’s because the first job of a new hire in the med-chem department is to crank out compounds, and that goes for both the PhD and Master’s levels. (Those roles diverge as time goes on, though). But with a few obvious rules in hand (no hot reactive functional groups, no huge greasy monster molecules, etc.), a person can contribute reasonable-looking compounds pretty quickly. No bi...
Source: In the Pipeline - April 15, 2008 Tags: How To Get a Pharma Job
Shall we have some drugs?
discuss this article
By now, everyone has heard about scientists using drugs to become smarter, better, faster like the Kanye West. For those under rocks, 20% of “scientists” have admitted to using performance enhancing drugs (a.k.a. Nootropics)- drugs which I’ve actually blogged about like Modafinil and other’s I have yet touched, like Ritalin.
The 1 in 5 number is a bit surprising, but it brought up a number of well written and freely accessible deliberations on the use of such drugs here. (Note the persistence of the age old practice of addressing letters to the editor as SIR. I demand righteous indignation be heape...
Source: The Chem Blog - April 15, 2008 Authors: Kyle Finchsigmate Tags: Drugs! Sciency politics
Fifteen Minutes Shot
discuss this article
If today's post didn't waste enough of your time, here's another way to carve something out of the economy: name all the elements, in any order but correctly spelled, in fifteen minutes.
I scored a 97 - forgot some of the more recently-named transition metals, and I didn't even bother with the placeholder names for 112 and up. Enjoy - and if you score higher than I did, don't forget to note that fact in the comments. Not that I have to tell anyone. . .
Source: In the Pipeline - April 14, 2008
A Meditation on Solvents
discuss this article
Hexane (or its cheaper, less well-defined cousin, petroleum ether) is the proto-solvent. Light and thin, it’s the weakest at actually dissolving anything, so it’s the background to most stronger mixtures in a purification. Like most other solvents, though, it’ll strip the oils right off your skin, leaving you spiderwebbed with white lines across your fingers and in need of some lotion. Its smell isn’t pleasant, but it doesn’t really stink, either. A nonchemist would easily place it in the oil / kerosene / gasoline end of things, which is exactly where it belongs.
When I first encountered ethyl acetate back in co...
Source: In the Pipeline - April 14, 2008 Tags: Life in the Drug Labs
Make some Oseltamivir with BMT
discuss this article
The Bird Flu is a ravaging disease that could kill quadrillions of people and is thus of paramount importance when an Angew. Chem. publication (DOI: 10.1002/anie.200800282) is on the line. Fortunately, before the disease can star pillaging and burninating, it can be stopped (STOPPED I TELL YOU!) by Roche’s Oseltamivir. The problem, as we all know, is that Oseltamivir’s starting material is synthesized from nothing less than the tongue of Caucasian baby fetuses (or Chinese Star anise) and it’s already simplistic biosynthesis in the bacterium who shall not be named is not to be discussed.
Very good. Now tha...
Source: The Chem Blog - April 13, 2008 Authors: Kyle Finchsigmate Tags: In teh lab Organic Chemistry
Free Sushi in the Cafeteria!
discuss this article
So Takeda has surprised the folks at Millennium with a buyout offer. (They're battening down the hatches over in Japan, and looking for something new). I know several people over at the latter company, and I can imagine that yesterday was one of the less productive days around the labs. No doubt there was a lot of initial fear that this would be a Pfizer-style deal (see below), but as the day went on that didn’t seem to be the case. I’m told that retention bonuses are being offered, along with several other features to try to keep the Millennium operation running.
Takeda’s been increasing its US presence over the ye...
Source: In the Pipeline - April 11, 2008 Tags: Business and Markets
Tellurium (It only gets worse as you keep going down)
discuss this article
As you go down the group, the smells only get worse. You don't smell oxygen (you're soaking in it), sulfur compounds tend to be pretty stinky, selenium compounds are pretty rank, and purportedly, tellurium compounds are the worst. Read the rest of this post... | Read the comments on this post...
Source: Molecule of the Day - April 10, 2008 Tags: Stinky
Exubera, Safety, and No Guarantees
discuss this article
As mentioned yesterday, I would have to say that Mannkind is in big trouble. I’d never heard of the company until the Wonder Drug Factory was closing back in Connecticut, but Mannkind was moving some of their operations into the state around then and interviewed a number of my former colleagues.
The whole inhaled-insulin idea had already taken some pretty severe blows. The massive failure of Exubera was the biggest, although a creative person could always argue that a better product with a more convenient delivery system could succeed in its place. But then Novo Nordisk and Eli Lilly (serious diabetes players, both of t...
Source: In the Pipeline - April 10, 2008 Tags: Diabetes and Obesity
